Evidence map›Paper›PMID 35337142›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Multiple Effects of Resveratrol on Osteosarcoma Cell Lines.

Angela De Luca, Daniele Bellavia, Lavinia Raimondi, Valeria Carina, Viviana Costa, Milena Fini, Gianluca Giavaresi

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Antimetastatic Effects of aAntioxidants (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Review
  7. The Functional Role of Polyphenols Across the Human Lifespan.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Special Issue "Osteosarcomas: Treatment Strategies".Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  17. Multi-Anticancer Activities of Phytoestrogens in Human Osteosarcoma.International journal of molecular sciences · 2023
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Angela De LucaIRCCS Istituto Ortopedico Rizzoli, CS Surgical Sciences and Technologies-SS Omics Science Platform for Personalized Orthopedics, 40136 Bologna, Italy.ORCID 0000-0001-5493-9441
Daniele BellaviaIRCCS Istituto Ortopedico Rizzoli, CS Surgical Sciences and Technologies-SS Omics Science Platform for Personalized Orthopedics, 40136 Bologna, Italy.ORCID 0000-0003-3308-9112
Lavinia RaimondiIRCCS Istituto Ortopedico Rizzoli, CS Surgical Sciences and Technologies-SS Omics Science Platform for Personalized Orthopedics, 40136 Bologna, Italy.ORCID 0000-0001-9394-2002
Valeria CarinaIRCCS Istituto Ortopedico Rizzoli, CS Surgical Sciences and Technologies-SS Omics Science Platform for Personalized Orthopedics, 40136 Bologna, Italy.ORCID 0000-0002-7323-8023
Viviana CostaIRCCS Istituto Ortopedico Rizzoli, CS Surgical Sciences and Technologies-SS Omics Science Platform for Personalized Orthopedics, 40136 Bologna, Italy.ORCID 0000-0002-2425-6460
Milena FiniIRCCS Istituto Ortopedico Rizzoli, CS Surgical Sciences and Technologies-SS Omics Science Platform for Personalized Orthopedics, 40136 Bologna, Italy.
Gianluca GiavaresiIRCCS Istituto Ortopedico Rizzoli, CS Surgical Sciences and Technologies-SS Omics Science Platform for Personalized Orthopedics, 40136 Bologna, Italy.ORCID 0000-0001-7843-5969
Istituto Ortopedico Rizzoli · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is the most common primary bone sarcoma affecting the life of pediatric patients. The clinical treatment faces numerous difficulties, including the adverse effects of chemotherapies, chemoresistance, and recurrences. In this study, the effects of resveratrol (RSV), a natural polyphenol, on OS cell lines were investigated to evaluate its action as an adjuvant therapy to the current chemotherapy regimens. RSV exhibited multiple tumor-suppressing activities on OS cell lines, inducing a series of critical events. We found (1) a cell growth inhibition due to an increase in cell distress, which was, in part, due to the involvement of the AKT and caspase-3 pathways, (2) an increase in cellular differentiation due to major gene expression levels of the osteoblastic differentiation genes, (3) an inhibition of IL-6 secretion due to an epigenetic effect on the IL-6 promoter, and (4) an inhibition of OS cells migration related to the decrease in IL-8 secretion levels due to an epigenetic effect on its promoter. Finally, the cotreatment of RSV with doxorubicin and cisplatin increased their cytotoxic effect on OS cells. Although further investigations are mandatory, it seems RSV might be a promising therapeutic adjuvant agent for OS cell treatment, exerting an antitumor effect when combined with chemotherapy.

Indexed as

apoptosischemotherapeutic agentscisplatindoxorubicininvasionnatural compoundosteosarcomaproliferationresveratrol

Identifiers

PMID35337142
PMCPMC8956103
OpenAlexW4220738084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.